drugset / Trial / NCT04699630
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
Timeline
- Start
- 2021-05-03
- Primary completion
- 2025-04-09
- Completion
- 2025-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Patritumab deruxtecan | Monoclonal antibody | 5.6 mg/kg | Intravenous |